Biomarkers are objective, measurable indicators of biological processes, used in clinical research and practice. They can be measured accurately and reproducibly, distinguishing them from symptoms, which are subjective. The article discusses the definitions and roles of biomarkers, surrogate endpoints, and clinical endpoints. Biomarkers are often used as surrogate endpoints in clinical trials, acting as substitutes for clinical endpoints. However, not all biomarkers are suitable as surrogates, as their predictive value for clinical outcomes must be validated. Surrogate endpoints require solid scientific evidence to accurately predict clinical outcomes. The use of biomarkers as surrogates can expedite drug development by providing interim data on treatment safety and efficacy. However, there are risks of misinterpreting biomarker data, leading to flawed conclusions. For example, some biomarkers used as surrogates have been shown to be poor predictors of clinical outcomes. The FDA allows the use of biomarkers as surrogate endpoints but requires follow-up studies to confirm their clinical relevance. Biomarkers should not replace clinical endpoints entirely, as their relationship to clinical outcomes is complex and requires ongoing evaluation. The article emphasizes the importance of distinguishing between biomarkers and clinical endpoints to ensure accurate research conclusions and safe treatment development.Biomarkers are objective, measurable indicators of biological processes, used in clinical research and practice. They can be measured accurately and reproducibly, distinguishing them from symptoms, which are subjective. The article discusses the definitions and roles of biomarkers, surrogate endpoints, and clinical endpoints. Biomarkers are often used as surrogate endpoints in clinical trials, acting as substitutes for clinical endpoints. However, not all biomarkers are suitable as surrogates, as their predictive value for clinical outcomes must be validated. Surrogate endpoints require solid scientific evidence to accurately predict clinical outcomes. The use of biomarkers as surrogates can expedite drug development by providing interim data on treatment safety and efficacy. However, there are risks of misinterpreting biomarker data, leading to flawed conclusions. For example, some biomarkers used as surrogates have been shown to be poor predictors of clinical outcomes. The FDA allows the use of biomarkers as surrogate endpoints but requires follow-up studies to confirm their clinical relevance. Biomarkers should not replace clinical endpoints entirely, as their relationship to clinical outcomes is complex and requires ongoing evaluation. The article emphasizes the importance of distinguishing between biomarkers and clinical endpoints to ensure accurate research conclusions and safe treatment development.